

533,988

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041311 A1

- (51) International Patent Classification⁷: **A61K 51/04**, C07F 9/50
- (21) International Application Number: PCT/EP2003/012128
- (22) International Filing Date: 31 October 2003 (31.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
02024803.5 7 November 2002 (07.11.2002) EP
- (71) Applicant (for all designated States except US): **BRACCO IMAGING S.P.A.** [IT/IT]; Via E. Folli, 50, I-20134 Milano (IT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **TISATO, Francesco** [IT/IT]; Via Barozzi, 9, I-35128 Padova (IT). **BOLZATI, Cristina** [IT/IT]; Via Martiri, 1, I-44037 Jolanda di Savoia (IT). **PORCHIA, Marina** [IT/IT]; Via Cappellini, 10, I-Via Cappellini 10, I-35100 Padova (IT). **REFOSCO, Florenzo** [IT/IT]; Via Libia, 24A, I-36078 Valdagno (IT).
- (74) Agents: **MINOJA, Fabrizio** et al.; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RADIOACTIVE TRANSITION METAL-IMIDO HETERO-DIPHOSPHINE COMPLEXES, THEIR PREPARATION AND RADIOPHARMACEUTICAL COMPOSITIONS THEREOF

(57) Abstract: The present invention provides radioactive metal heterocomplexes of formula (I): $[(\text{Me}=\text{N}-\text{R}) \text{L}_1 \text{L}_2] + \text{Z}$ (I), wherein Me, R, L^1 , L^2 and Z have the meanings indicated in the description. The complexes include a trivalent radioactive metal-imido group, typically a technetium- or rhenium-imido group, strongly stabilized by the presence of an ancillary tridentate hetero-diphosphine ligand L^1 , which allows the formation of substitution-inert $[(\text{Me}=\text{N}-\text{R})\text{L}^1]$ moieties. Such moieties are fixed in an intermediate $[(\text{Me}=\text{N}-\text{R})\text{Y}_2\text{L}^1]^+$ compound which contains two labile, cispositioned, Y ligands, where Y is preferably an halide group. The latter are easily replaced by a bidentate ligand L^2 to give the final $[(\text{Me}=\text{N}-\text{R})\text{L}^1\text{L}^2]^+ \text{Z}^-$ heterocomplexes. The complexes of the invention are useful for the preparation of radiopharmaceuticals: in fact, a bioactive fragment which confers biological target-seeking properties can be introduced either on the L^2 framework or the imido R group.

WO 2004/041311 A1

**RADIOACTIVE TRANSITION METAL-IMIDO HETERO-DIPHOSPHINE
COMPLEXES, THEIR PREPARATION AND RADIOPHARMACEUTICAL
COMPOSITIONS THEREOF**

Field of the invention

The present invention relates to a radioactive transition metal-imido heterocomplex, a radiopharmaceutical comprising said complex and a process for producing thereof. More particularly, the complex of the invention
5 comprises an imido derivative of radioactive technetium or rhenium and two different ligands coordinated therewith.

State of the art

The ^{99m}Tc -imido core has been only generically cited among a series of new cores suitable for the development of technetium radiopharmaceuticals
10 (Archer C. *et al.* WO 91/03262 and references therein). Despite a few examples obtained at "carrier added (ca)" or, in other words, macroscopic level, using ^{99}Tc and cold Re, in which the presence of the imido group was clearly established, the transfer of this chemistry at "no carrier added (nca)" or, in other words, microscopic level, has met severe obstacles so far. The
15 terms "macroscopic" or "carrier added" level refer to chemical reactions occurring at concentrations ranging from 10^{-3} to 10^{-5} M. Reactions are performed in conventional laboratories (if necessary approved for low level radioactivity) using from 1 to 200 mg amounts of non-radioactive Re or radioactive ^{99}Tc . The terms "microscopic" or "no carrier added" level refer to
20 reactions occurring at concentrations ranging from 10^{-6} to 10^{-9} M with micrograms to nanograms amounts of radioactive ^{99m}Tc or of radioactive ^{188}Re (see also IUPAC Compendium of Chemical Terminology, 2nd Edition (1997), wherein the following definition is provided for "no carrier added": "...a preparation of a radioactive isotope which is essentially free from stable

isotopes of the element in question..."). These reactions are routinely performed in hospital Nuclear Medicine Departments for clinical purposes (Deutsch, E., Libson, K., *Recent advances in technetium chemistry: bridging inorganic chemistry and nuclear medicine*, Comments Inorg. Chem., 3, 83-
5 103, 1984).

Working at macroscopic level with ^{99}Tc , only five crystal structures of Tc(V)-imido species have been reported. They include $[\text{Tc}(\text{NR})\text{Cl}_3(\text{PPh}_3)_2]$, where R is phenyl (Nicholson T. *et al.* Inorg. Chim. Acta, 187 (1991) 51) or tolyl (Dilworth J. *et al.* in *Technetium in Chemistry and Nuclear Medicine* – 3, 10 Raven Press, New York, (1990), 109). By varying the bulkiness of both the halide (from Cl to Br) and/or the phosphine (from PPh_3 to PMePh_2 and PMe_2Ph), three additional phenyl-imido compounds have been produced, i.e.: $[\text{Tc}(\text{NPh})\text{Cl}_3(\text{PMePh}_2)_2]$, $[\text{Tc}(\text{NPh})\text{Br}_3(\text{PMePh}_2)_2]$ (Rochon F.D. *et al.* *Inorg. Chem.* 34 (1995) 2273) and $[\text{Tc}(\text{NPh})\text{Cl}_2(\text{PMe}_2\text{Ph})_3]^+$ (Nicholson T. *et al.* 15 *Inorg. Chim. Acta*, 230 (1995) 205).

Nevertheless, no specific disclosure, nor even suggestions, have ever been made on the possibility of successfully transferring the above preparations also at microscopic level.

All the above species are six-coordinated compounds with slight
20 distortion from the ideal octahedron. The co-ordination sphere is totally filled with monodentate ligands (halides and monophosphines) that do not impose heavy steric constraints. In this connection the Tc atom moves off the mean basal plane towards the imido unit by only 0.11 Å. The imido core is essentially linear (mean Tc=N-C angle 175.7°) with a marked portion of the
25 Tc-N bond showing double bond character (mean value 1.71 Å; see G. Bandoli *et al.*, *Coord. Chem. Rev.*, 214 (2001) 43).

The possibility to introduce chelate ligands in the co-ordination sphere of Tc(V)-imido compounds was demonstrated separately by different authors.

Nicholson et al. (*Inorg. Chim. Acta*, 196 (1992) 27) introduced a simple bidentate diphosphine, *i.e.* 1,2-bis (diphenylphosphine)ethane (dppe) to yield $[\text{Tc}(\text{NPh})\text{Cl}_3(\text{dppe})]$. Tisato et al. (*J. Organom. Chem.* 637-639 (2001) 772) utilised the 1,2-bis (diphenylphosphine)ferrocenyl residue (dppf) to produce
5 the analogous $[\text{Tc}(\text{NPh})\text{Cl}_3(\text{dppf})]$ complex. Similarly, rhenium (Re) complexes were synthesized, by using the bidentate (2-diphenylphosphine)benzeneamine (H_2dpa), or the tetradentate N,N' -bis[(2-diphenylphosphine)phenyl]propane-1,3-diamine (Refosco F. *et al*, *J. Chem. Soc. Dalton Trans* 1998, 923-930).

10 Notwithstanding the above results, successive extensive efforts to stabilize the $^{99\text{m}}\text{Tc}$ -imido core have surprisingly failed, because no appropriate combinations of donor atoms was found to support this group, while, on the contrary, this target was successfully achieved in the case of the somewhat similar $^{99\text{m}}\text{Tc}$ -oxo and $^{99\text{m}}\text{Tc}$ -nitrido cores. Oxo $[\text{Ox}^{99\text{m}}\text{Tc}(\text{O})]^{3+}$, imido
15 $[\text{Im}^{99\text{m}}\text{Tc}(\text{NR})]^{3+}$ and nitrido $[\text{Nit}^{99\text{m}}\text{Tc}(\text{N})]^{2+}$ moieties are isoelectronic cores, the metal being in the 5^+ oxidation state, and, in this connection, the technetium-imido group can be considered as intermediate between oxo and nitrido cores. Previous investigations have established that $\text{Tc}(\text{V})$ -oxo groups are readily stabilized by tetradentate ligands, as shown by N_4 -hexamethylpropylene amine
20 oxime (HM-PAO), N_3S -mercaptoacetyltriglycyl (MAG_3) and N_2S_2 -ethylcysteine dimer (ECD) in the clinically used Ceretec[®], Technescan[®] and Neurolite[®] radiopharmaceuticals. On the other hand, the $\text{Tc}(\text{V})$ -nitrido group prefers a combination of two different polydentate ligands. Previous studies on ^{99}Tc -imido complexes have shown that distorted octahedral environments are
25 usually achieved, the coordination being supported by monodentate ligands, preferably tertiary monophosphines and halides. Attempts to replace the monodentate P-based donors present in the prototype precursor $[\text{Tc}(\text{NPh})\text{Cl}_3(\text{PPh}_3)_2]$ with various polydentate chelates were not successful,


thus indicating that the imido group should be stabilized only by the presence of monodentate monophosphine ligands.

Description of the invention

It has now surprisingly been found that it is possible to replace the two monodentate triphenylphosphine substituents with a tridentate hetero-diphosphine ligand L^1 which comprises an electron donor heteroatom in the spacer chain linking said two phosphine groups, without affecting the stability of the imido group in the resulting $[(Me=N-R)Y_2(L^1)]^+Y^-$ compounds, wherein Y is a leaving group, such as a halogen atom, an hydroxy or an alkoxy group.

The facial configuration of the tridentate hetero-diphosphine chelate induces a *cis*-coordination of the two Y groups, which in turn can be easily substituted with suitable bidentate ligands L^2 to give the final desired $[(Me=N-R)L^1L^2]^+Z^-$ metal heterocomplex.

Accordingly, the present invention primarily provides a radioactive transition metal-imido hetero-diphosphine complex compound of formula (I):




wherein:

Me is a radioactive transition metal selected from the group consisting of ^{99m}Tc , ^{186}Re , ^{188}Re ;

R is a C_1 - C_{15} linear or branched alkyl or alkenyl residue, optionally interrupted by -O-, -S-, -N(R')-, where R' is H or C_1 - C_6 alkyl, and/or optionally substituted with halogen, hydroxy, C_1 - C_5 alkoxy, carboxy, ester, thiol, primary or secondary amino or amido groups, or R is phenyl or an aryl residue, being R optionally substituted with a biologically active substance, wherein said biologically active substance is selected among sugars, amino acids, fatty acids, vitamins, hormones, peptides, catecholamines, said catecholamines being optionally conjugated, via peptidic bond, to the other above mentioned biologically active substances;

L^1 is a tridentate hetero-diphosphine ligand of formula (II):



(II),

wherein:

R^1 , R^2 , R^3 and R^4 , which may be the same or different, have the same
5 meanings as R;

X is oxygen, sulphur, NR^5 , wherein R^5 is hydrogen or R;


n is an integer ranging from 1 to 5;

L^2 is a bidentate ligand, which comprises a combination of two donor
atoms, selected from the group consisting of oxygen, sulphur and nitrogen,
10 said atoms being preferably negatively charged and being separated by a
spacer of 2 to 4 members, said spacer being an aliphatic chain or part of an
aromatic ring, L^2 being optionally conjugated to a biologically active
substance as above defined;

Z^- is a mononegative counter-ion selected from the group consisting of Cl^- ,
15 Br^- , OH^- , ClO_4^- , alkoxylate, preferably EtO^- , tetrafluoroborate.

Preferred R are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, octyl,
decyl, dodecyl, propenyl, butenyl, pentenyl, phenyl, benzyl, tolyl, 4-methoxy-
benzyl, 4-ethoxy-benzyl, salicyl.

Preferred tridentate hetero-diphosphine ligands L^1 of formula (II) are
20 those where $n = 2$. Most preferred ligands L^1 are selected from the group
consisting of:






Bidentate ligands L^2 preferably comprise a 2 or 3 membered spacer as defined above between the two electron-donor atoms. Suitable combinations of electron-donor atoms, preferably negatively charged, are $[O^-, O^-]$, $[N^-, O^-]$, $[S^-, O^-]$, $[N^-, N^-]$, $[N^-, S^-]$ and $[S^-, S^-]$. Preferred bidentate ligands are catecholate⁽²⁻⁾; carbonate⁽²⁻⁾; 1,2-aminophenolate⁽²⁻⁾; 1,2-benzenedithiolate⁽²⁻⁾; ethyleneglycolate⁽²⁻⁾; ethylenediaminate⁽²⁻⁾; ethylenedithiolate⁽²⁻⁾; 1,2-phenylenediaminate⁽²⁻⁾; 1,2-aminothiophenolate⁽²⁻⁾; thiosalicylate⁽²⁻⁾; 1,2-aminoethanolate⁽²⁻⁾ and the like.

The bidentate ligands L^2 preferably carry a biologically active substance as defined above. Among said biologically active substances, preferred are catecholamines, like dopamine, L-DOPA and 3-hydroxytyramine. Catecholamines may, in turn, be conjugated, via peptidic bond, to other physiologically active substances. In a preferred embodiment of the invention, vitamin H is conjugated to dopamine.

The radioactive compounds of formula (I) can be obtained by reacting an intermediate compound of formula (III):



with a bidentate ligand L^2 ,


wherein Me, R, L^1 and L^2 are as defined above and Y is halogen, preferably chlorine, or bromine, hydroxy or alkoxy, preferably ethoxy, or a leaving group which easily undergoes nucleophilic substitution.

The reaction is usually carried out in an organic solvent, in the presence of an organic base, or under buffered conditions, preferably in phosphate buffer. Preferred solvents are alcohols and chlorinated solvents. Preferred organic bases are tertiary amines, more preferred is triethylamine. The reaction temperature ranges from room temperature to the reflux temperature of the solvent.

The final product is separated and purified with conventional techniques like salification, crystallization, chromatography as described in detail in the following experimental section.

Intermediate compounds of formula (III) are in turn synthesized as described in Scheme 1 below from oxides of radioactive transition metals, preferably $^{99m}\text{TcO}_4^-$, $^{186}\text{ReO}_4^-$ or $^{188}\text{ReO}_4^-$, more preferably $^{99m}\text{TcO}_4^-$, which are treated with an excess of tertiary monophosphines, preferably PPh_3 , in acidic hydro-alcoholic solutions and in the presence of a suitable imido donor (D), to give an imido complex of formula (IV), wherein Me, R and Y are as defined above. Successive treatment with an above described ligand L^1 affords the desired intermediates of formula (III).

Scheme 1



Suitable imido donors D according to the invention are preferably 1-substituted-2-acetyl hydrazine, most preferably 1-phenyl-2-acetyl hydrazine (PAH).

The reaction of L^1 with imido complexes of formula (IV) is preferably carried out in organic solvents like alcohols, chlorinated solvents, acetonitrile or a mixture thereof, optionally in the presence of an organic base like triethylamine, at a temperature ranging from room temperature to the reflux temperature of the solvent. The final purification of the desired intermediate of formula (III) is thoroughly described in the following experimental section. It has finally been demonstrated that the preferred ^{99m}Tc -imido heterocomplexes according to the invention can be obtained at microscopical level *via* a three-step approach starting from pertechnetate sodium salt eluted

from a commercial $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$ generator. In the first step pertechnetate is treated with an excess of tertiary monophosphine in hydro-alcoholic solutions acidified with hydrochloric acid and in the presence of 1-phenyl-2-acetylhydrazine. In the second step, addition of the tridentate hetero-diphosphine ligand in an organic solvent affords the intermediate species $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})\text{Cl}_2(\text{L}^1)]^+\text{Y}^-$. By adjusting pH at 7.4 with phosphate buffer, and by adding the preferred bidentate ligand L^2 , the desired imido heterocomplex is produced in high radiochemical yield (see Table 1).

Preferred complexes of the invention are:

- 10 $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})(\text{PNHP})(\text{O},\text{N-ap})]$;
 $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})(\text{PNHP})(\text{O},\text{O-car})]$;
 $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})(\text{PNMeP})(\text{O},\text{N-ap})]$;
 $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})(\text{PNMeP})(\text{S},\text{N-atp})]$;
 $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})(\text{PNMeP})(\text{O},\text{O-cat})]$;
15 $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})(\text{PNMeP})(\text{S},\text{O-tsal})]$;
 $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})(\text{PNMeP})(\text{S},\text{S-bdt})]$;

wherein

PNHP means $(\text{C}_6\text{H}_5)_2\text{PCH}_2\text{CH}_2\text{N}(\text{H})\text{CH}_2\text{CH}_2\text{P}(\text{C}_6\text{H}_5)_2$;

PNMeP means $(\text{C}_6\text{H}_5)_2\text{PCH}_2\text{CH}_2\text{N}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{P}(\text{C}_6\text{H}_5)_2$;

20 O,N-ap means 2-aminophenolate $^{(2-)}$;

S,N-atp means 2-aminothiophenolate $^{(2-)}$;

O,O-cat means catecholate $^{(2-)}$;

O,O-car means carbonate $^{(2-)}$;


S,O-tsal means thiosalicylate $^{(2-)}$;

25 S,S-bdt means 1,2-benzenedithiolate $^{(2-)}$

The reactivity of imido-containing species has been thoroughly studied at macroscopic level using $[\text{}^{99}\text{Tc}(\text{NPh})\text{Cl}_3(\text{PPh}_3)_2]$ and $[\text{Re}(\text{NPh})\text{Cl}_3(\text{PPh}_3)_2]$ as precursors.

These precursors react with tridentate hetero-diphosphine ligands L^1 to yield intermediate compounds of the type $[\text{Me}(\text{NPh})\text{Cl}_2\text{L}^1][\text{Cl}]$. The hetero-diphosphine ligand acts as a tridentate donor due to the presence of the electron-donor X heteroatom interposed in the diphosphine chain and gives rise to three different octahedral configurations, shown by the following

5 formulas (IIIA): *fac,cis* (IIIB) *mer,cis* and (IIIC) *mer,trans*.



In formulae (IIIA), (IIIB) and (IIIC) *a* denotes the positions occupied by ligand L^1 and *b* denotes the positions occupied by ligand Y.

10 The halide group, positioned *trans* with respect to the imido core in the intermediate *mer,cis*- $[\text{Me}(\text{NPh})\text{Cl}_2(\text{L}^1)]^+$ compounds, easily undergoes substitution with nucleophilic ligands (such as ethanolate), indicating that halide ligands are labile and good leaving groups. In similar substitution reactions, *cis*-positioned halides are replaced by bidentate nucleophilic ligands

15 such as ethyleneglycol or catechol or the like to yield imido heterocomplexes of the type $[\text{Me}(\text{NPh})\text{L}^1\text{L}^2]^+\text{Z}^-$. Thus, both *mer,cis*- $[\text{Me}(\text{NPh})\text{Cl}_2\text{L}^1]^+$ and *fac,cis*- $[\text{Me}(\text{NPh})\text{Cl}_2\text{L}^1]^+$ isomers are useful intermediates for the production of mixed imido heterocomplexes. On the contrary, the *mer,trans*- $[\text{Me}(\text{NPh})\text{Cl}_2\text{L}^1]^+$ isomers give rise to the heterocomplexes in a negligible

20 yield, as a result of heavy steric constraints imposed by the meridional coordination of the L^1 diphosphine combined with the *trans*-halide configuration. Thus, a reciprocal *cis*-position of the halide groups in the intermediate compounds is an essential pre-requisite for obtaining

heterocomplexes of the invention.

The stereochemistry of the L^1 ligand in the final heterocomplex is always facial, the bidentate ligand L^2 filling the residual two positions on the equatorial plane of the octahedron.

5 The present invention is illustrated in further detail in the following examples.

EXAMPLES

The tridentate hetero-diphosphine ligands L^1 and the bidentate ligands L^2 used in the following examples are abbreviated as follows:

10 Tridentate hetero-diphosphine ligands L^1 :

PNHP	; (C ₆ H ₅) ₂ PCH ₂ CH ₂ N(H)CH ₂ CH ₂ P(C ₆ H ₅) ₂
PNMeP	; (C ₆ H ₅) ₂ PCH ₂ CH ₂ N(CH ₃)CH ₂ CH ₂ P(C ₆ H ₅) ₂
MePNMePMe	; (CH ₃) ₂ PCH ₂ CH ₂ N(CH ₃)CH ₂ CH ₂ P(CH ₃) ₂
PNOMeP	; (C ₆ H ₅) ₂ PCH ₂ CH ₂ N(CH ₂ CH ₂ OCH ₃)CH ₂ CH ₂ P(C ₆ H ₅) ₂
15 POP	; (C ₆ H ₅) ₂ PCH ₂ CH ₂ OCH ₂ CH ₂ P(C ₆ H ₅) ₂
PSP	; (C ₆ H ₅) ₂ PCH ₂ CH ₂ OCH ₂ CH ₂ P(C ₆ H ₅) ₂

Bidentate ligands L^2 :

O,O-cat	; catecholate ⁽²⁻⁾
O,O-car	; carbonate ⁽²⁻⁾
20 N,N-pda	; 1,2-phenylenediaminate ⁽²⁻⁾
S,S-bdt	; 1,2-benzenedithiolate ⁽²⁻⁾
O,O-eg	; ethyleneglycolate ⁽²⁻⁾
N,N-en	; ethylenediaminate ⁽²⁻⁾
S,S-edt	; ethylenedithiolate ⁽²⁻⁾
25 O,N-ap	; 1,2-aminophenolate ⁽²⁻⁾
S,N-atp	; 1,2-aminothiophenolate ⁽²⁻⁾
O,S-tsal	; thiosalicylate ⁽²⁻⁾
O,N-ae	; 1,2-aminoethanolate ⁽²⁻⁾

Chemistry at macroscopic (ca) level by using ^{99}Tc and Re**Example 1: Synthesis of *mer,cis*- $^{99}\text{Tc}(\text{NPh})\text{Cl}_2(\text{PNHP})][\text{Cl}]$**

To a solution of $[\text{Tc}(\text{NPh})\text{Cl}_3(\text{PPh}_3)_2]$ (45 mg) in dichloromethane/methanol (5 mL/1 mL) a 1.1 equivalent of solid PN(H)P was added under stirring. The brown mixture, in 2 minutes, turned brown-green. After 3 h the solution was taken to dryness with a flow of nitrogen. The oily residue was treated with diethyl ether and the resulting brown-green solid filtered. The crude solid was washed on the filter with acetone (2 mL). The light green solid was dried under nitrogen (yield 22 mg, 60%). The product is soluble in chlorinated solvents and acetonitrile, slightly soluble in alcohols, insoluble in diethyl ether.

^{31}P -NMR (300 MHz, CDCl_3 , ppm): 31.6 (bs).

^1H -NMR (300 MHz, CDCl_3 , ppm): 9.70 (bs, 1H; N-H), 8.06 (m, 4H, PPh_2), 7.51 (m, 13H, $\text{PPh}_2 + \text{NPh}_{\gamma,\alpha}$), 7.02 (m, 6H, PPh_2), 6.86 (t, 2H, NPh_β), 3.97 (bt, 2H, CH_2), 3.34 (bm, 6H, CH_2).

Example 2: Synthesis of *mer,cis*- $[\text{Re}(\text{NPh})\text{Cl}_2(\text{PNHP})][\text{Cl}]$

To a suspension of $[\text{Re}(\text{NPh})\text{Cl}_3(\text{PPh}_3)_2]$ (104 mg, 0.11 mmol) in CH_2Cl_2 , an excess of $\text{PNHP}\cdot\text{HCl}$ (75 mg, 0.16 mmol) dissolved in CH_2Cl_2 with 50 μl of NEt_3 (0.38 mmol) was added dropwise. The reaction mixture was refluxed for 2 hours and then stirred overnight at room temperature. The resulting solution was olive-green. The solvent was removed and the green solid washed with diethyl ether, water and dried under vacuum. The ^{31}P -NMR spectrum of such solid in CDCl_3 showed two peaks at 4.3 and 8.4 ppm, which suggest the presence of two new products. A pure product was obtained by crystallization from a CH_2Cl_2 /n-hexane mixture. Grey-blue crystals were obtained (final yield 30-40%) and the compound was identified as $[\text{Re}(\text{NPh})\text{Cl}_2(\text{PN}(\text{H})\text{P})]\text{Cl}$. The product is stable in air and soluble in CH_2Cl_2 , CHCl_3 , quite soluble in EtOH and MeOH, insoluble in H_2O , hexane and Et_2O .

^{31}P -NMR (300 MHz, CDCl_3 , ppm): 8.48 (s).

^1H -NMR (300 MHz, CDCl_3 , ppm): 8.07(m, 4H, PPh_2), 7.71 (d, 2H,), 7.50 (m, 11H, $\text{PPh}_2 + \text{NPh}\gamma$), 7.03 (m, 6H, PPh_2), 6.87 (t, 2H, $\text{NPh}\beta$), 4.01 (bt, 2H, CH_2), 3.39 (bm, 2H, CH_2), 3.22 (bm, 4H, CH_2), 9.5 (b, 1H, NH).

5 **Example 3: Synthesis of *mer,cis*-[Re(NPh)(OEt)Cl(PNHP)][Cl]**

To a suspension of $[\text{Re}(\text{NPh})\text{Cl}_3(\text{PPh}_3)_2]$ (52 mg, 0.057 mmol) in EtOH, an excess of PNHP·HCl (43 mg, 0.089 mmol) dissolved in EtOH with 25 μl of NEt_3 (0.19 mmol) was added dropwise. The reaction mixture was refluxed for 4 hours: the resulting solution was green-yellowish. The volume was reduced under a nitrogen stream and Et_2O was added: after few hours large bright blue crystals of $[\text{Re}(\text{NPh})(\text{OEt})\text{Cl}(\text{PNHP})]\text{Cl}$ had been formed.

^{31}P -NMR (300 MHz, CDCl_3 , ppm): -0.20 (s).

10 ^1H -NMR (300 MHz, CDCl_3 , ppm): 9.5 (b, 1H, NH), 8.00 (m, 4H, PPh_2), 7.53 (m, 13H, $\text{PPh}_2 + \text{NPh}$), 7.07 (m, 6H, PPh_2), 6.87 (t, 2H, $\text{NPh}\beta$), 3.99 (bt, 2H, CH_2), 3.41 (m, 2H, CH_2), 3.18 (m, 2H, CH_2), 2.98 (m, 2H, CH_2), 2.64 (q, 2H; O- CH_2 - CH_3), -0.13 (t, 3H; O- CH_2 - CH_3).

Example 4: Synthesis of *fac,cis*-[Re(NPh)Cl₂(PNMeP)][Cl]

To a suspension of $[\text{Re}(\text{NPh})\text{Cl}_3(\text{PPh}_3)_2]$ in CH_2Cl_2 a slight excess of PNMeP (86 mg, 0.19 mmol) was added. The reaction mixture was refluxed for 20 24 h. The volume of the resulting green-yellowish solution was reduced and Et_2O was added. A TLC analysis of the precipitate showed a mixture of different products, so separation by means of a chromatographic column was performed (silica gel, $\text{CHCl}_3/\text{EtOH}$ 3/2). Two yellow and a green fraction were collected. The green product was identified as $[\text{Re}(\text{NPh})\text{Cl}_2(\text{PNMeP})]\text{Cl}$.

25 $^{31}\text{P}\{\text{H}\}$ -NMR (300 MHz, CDCl_3 , ppm): 19.9 (s).

^1H -NMR (300 MHz, CDCl_3 , ppm): 4.08, 3.45 and 2.95 (m, 8H CH_2), 2.61 (s, 3H, CH_3).

Example 5: Synthesis of *mer,trans*-[Re(NPh)Cl₂(PNMeP)][Cl]

[Re(NPh)Cl₃(PPh₃)₂] (100 mg, 0.11 mmol) and PNMeP·HCl (86 mg, 0.17 mmol) were mixed in acetonitrile. By refluxing for 15 minutes the reaction mixture became light green. Additional reflux deposited a green solid within a few hours. After 4 h the mixture was allowed to reach room temperature and filtered. The green powder was washed with Et₂O and resulted soluble in CH₂Cl₂, quite soluble in CHCl₃ and almost insoluble in Et₂O and benzene. NMR analysis evidenced the presence of two isomers in solution (yield 70%), then characterised as *cis*-[Re(NPh)Cl₂(PNMeP)]Cl·HCl.

¹H-NMR (300 MHz, CD₂Cl₂, ppm): 6.59 (d); 6.74 (t); 7.45 (t) (5H, NPh); 7.10 (m); 7.24 (m); 7.37 (m); 7.55 (m); 7.70 (m); 7.85 (m); 7.96 (m) (20H, PPh₂); 3.74(m); 3.35 (m); 3.08 (m) (8H, CH₂); 2.99 (d); 2.69 (d) CH₃. ³¹P {H} NMR (300 MHz, CD₂Cl₂, ppm): -25.1 (s); -26.9 (s). The pale-green powder (*cis*-[Re(NPh)Cl₂(PNMeP)]Cl·HCl) was dissolved in CH₂Cl₂ in the presence of an excess of NEt₃. NMR analysis evidenced the quantitative conversion into the *mer,trans*-[Re(NPh)Cl₂(PNMeP)]Cl complex.

³¹P-NMR (300 MHz, CDCl₃, ppm): 19.9 (s)

¹H-NMR (CDCl₃, ppm) = 7.6-7.1 (20H; PPh₂) 4.08, 3.45 and 2.95 (m, 8H; methylene protons); 2.61 (s, 3H; CH₃).

Example 6: Synthesis of *fac*-[⁹⁹Tc(NPh)(O,O-cat)(PNHP)][ClO₄]

To a solution of [⁹⁹Tc(NPh)Cl₂(PNHP)][Cl], prepared according to Example 1, (26 mg, 0.04 mmol) in methanol (5 mL), catechol (5.2 mg, 0.047 mmol) and triethylamine (6.7 μL, 0.047 mmol) were added. The colour of the mixture turned immediately deep purple. The solution was stirred for 4 h and concentrated to 2 mL by a nitrogen flow. A drop of a saturated NaClO₄ solution in MeOH was added to the solution. After 1 day, dark-grey crystals were formed; they were collected on a filter and washed with a 1x2 mL of MeOH.

^{31}P -NMR (300 MHz, CDCl_3 , ppm): 46.5 (bs).

^1H -NMR (300 MHz, CDCl_3 , ppm): 7.77 (t, 4H), 7.49 (t, 4H), 7.40 (t, 4H), 7.22 (m, 6H) 7.02 (m, 7H), 6.87 (m, 2H), 6.71 (m, 2H), 3.5 – 2.7 (8H).

Example 7: Synthesis of *fac*-[Re(NPh)(O,O-cat)(PNHP)][Cl]

5 To a bluish solution of $[\text{Re}(\text{NPh})\text{Cl}_2(\text{PNHP})]\text{Cl}$, prepared according to Example 2, in CH_2Cl_2 (40 mg, 0.05 mmol) catechol (H_2cat) (5 mg, 0.045 mmol) and 20 μl of NEt_3 were added at room temperature. The reaction mixture immediately turned red. The solution was stirred overnight at room temperature. After 15 h the solvent was removed, the residue was treated with
10 diethyl ether and the resulting red-brown solid filtered and washed several times with n-hexane, diethyl ether and water. $[\text{Re}(\text{NPh})(\text{O},\text{O-cat})(\text{PNHP})]\text{Cl}$ was obtained with a final yield of 53%. ^1H -NMR (300 MHz, CDCl_3): 7.85-7.07 (m, 25H, *NPh* and *PPh*₂), 6.91-6.73 (m, 4H, *catH*). ^{31}P -NMR: 19.5 (s). A stoichiometric amount of NBu_4BF_4 was added to a CH_2Cl_2 solution of
15 $[\text{Re}(\text{NPh})(\text{O},\text{O-cat})(\text{PNHP})]\text{Cl}$ and by addition of n-hexane a red-orange product precipitated. According to the elemental analysis, this powder was characterized as the tetrafluoroborate salt of $[\text{Re}(\text{NPh})(\text{O},\text{O-cat})(\text{PNHP})]$.

^{31}P -NMR: 19.5 (s).

El. Anal.: $\text{ReN}_2\text{C}_{40}\text{H}_{38}\text{O}_2\text{P}_2\text{BF}_4$, MW 913.7

20 Calcd. C 52.6, N 3.2, H 5.1

Found: C 52.9, N 3.2, H 5.1.

Example 8: Synthesis of *fac*-[Re(NPh)(O,O-eg)(PNHP)][Cl]

To a bluish solution of $[\text{Re}(\text{NPh})\text{Cl}_2(\text{PNHP})]\text{Cl}$ of Example 2 in CH_2Cl_2 (40 mg, 0.05 mmol) 30 μl of ethylene glycol and 20 μl of NEt_3 were added at
25 room temperature. The reaction mixture was refluxed for 1 h and then stirred at room temperature for 24 h. The solution became grey. After removal of the solvent with a gentle nitrogen stream, the oily residue was treated with diethyl ether and the resulting grey solid filtered. The crude solid was purified

washing, on the filter, with n-hexane and water. Grey crystals of $[\text{Re}(\text{NPh})(\text{O},\text{O-eg})(\text{PNHP})]\text{Cl}$, suitable also for X-ray diffractometric analysis, were obtained by crystallization from a $\text{CH}_2\text{Cl}_2/\text{n-hexane}$ solution. ^{31}P {H} NMR (300 MHz, CD_2Cl_2) 17.2. ^1H -NMR (300 MHz, CDCl_3): 7.74-6.91 (m, 25H, *NPh* and *PPh*₂), 4.98 (b, 1H, *NH*), 4.78 (d, 2H, *CH*₂), 4.60 (d, 2H, *CH*₂), 3.2-2.9 (m, 8H, *PCH*₂*CH*₂*N*).

Example 9: Synthesis of *fac*-[Re(NPh)(O,O-eg)(PNMeP)][Cl]

To a solution of *fac,cis*-[Re(NPh)Cl₂(PNMeP)]Cl of Example 4 in CH_3CN (50 mg, 0.06 mmol) 30 μl of ethylene glycol and 20 μl of NEt_3 were added. The reaction mixture was refluxed for 24 h. The volume of the dark green solution was reduced and the oily residue was dissolved in CH_2Cl_2 . The excess of ethylene glycol was removed by water extraction. The organic phase was dried and a green powder, characterised as *fac*-[Re(NPh)(O,O-eg)(PNMeP)]Cl was recovered (yield 43%).

^1H -NMR (300 MHz, CDCl_3 , δ ppm): 6.98 – 7.48 (m, 25H, *NPh* and *PPh*₂); 4.91-4.76 (m, 4H *CH*); 3.58 (m), 3.27 (m) e 2.27 (m) (8H, $-\text{CH}_2\text{CH}_2-$ PNP; 2.34 (s, 3H, *N-CH*₃).

^{31}P (CDCl_3): = 24.3 (s).

Example 10: Synthesis of *fac*-[Re(NPh)(O,N-ap)(PNMeP)][Cl]

To a suspension of $[\text{Re}(\text{NPh})\text{Cl}_3(\text{PPh}_3)_2]$ in CH_2Cl_2 (90 mg, 0.1 mmol) PNMeP (53 mg, 0.11 mmol) was added at room temperature. After 5 minutes 1,2 aminophenol (17 mg, 0.16 mmol) and 20 μl of NEt_3 were added and the reaction mixture was refluxed. After 10 minutes the solution turned from green to dark brown. After refluxing for 30 min the solution was stirred overnight at room temperature. The solvent was removed and the residue treated with diethyl ether. The red brown solid was filtered and re-dissolved in CH_2Cl_2 . Elution from a silica column with $\text{CHCl}_3/\text{MeOH}$ 85/15 separated a yellow by-product and the red *fac*-[Re(NPh)(O,N-ap)(PNMeP)]Cl.

^{31}P (CDCl_3): = 17.8 (d), 10.1 (d).

Chemistry at microscopic (nca) level by employing $^{99\text{m}}\text{Tc}$

Example 11: Synthesis of the intermediate $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})\text{Cl}_2 \text{L}^1]^+\text{Y}^-$.

0.1 mL of saline physiological solution containing $[\text{}^{99\text{m}}\text{TcO}_4]^-$ (50 Mbq) were added to a vial containing 10 mg of PAH, 3 mg of PPh_3 0.1 mL of 1 M HCl and 1.5 mL of MeOH. The resulting solution was heated at 65°C for 30 min. After this, 0.2 mL of an alcoholic solution containing 3 mg of an appropriate L^1 hetero-diphosphine ligand (PNHP or PNMeP or PNOMeP) was added. The resulting solution was maintained at 65°C for further 30 min.

TLC analysis of the intermediate $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})\text{Cl}_2 \text{L}^1]^+$ species showed a mixture of different products. This behaviour is in agreement with the evidences produced at macroscopic level, where some intermediate species were characterised.

Example 12: Synthesis of $[\text{}^{99\text{m}}\text{Tc}(\text{NPh}) \text{L}^1 \text{L}^2]^+\text{Z}^-$.

This three-step preparation involves the preliminary formation of a mixture of intermediate complexes of general formula $[\text{}^{99\text{m}}\text{Tc}(\text{NPh})\text{Y}_2 \text{L}^1]$ (Y = halides, water, hydroxyl, alkoxy) followed by its conversion into the final asymmetrical compound by reactions with the bidentate ligand L^2 . In detail, 0.250 mL of phosphate buffer 1 M, pH 7.4, followed by 0.2 mL of methanol solution containing 5 mg of an appropriate bidentate ligand L^2 were added to the vial containing the intermediate compound, obtained as reported above. The mixture was heated at 65°C for 1h. The radiochemical yields evaluated by TLC chromatography are reported in Table 1.

Table 1: TLC SiO₂:^a EtOH/CHCl₃/C₆H₆ (1/2/1.5); ^bCHCl₃/MeOH (2% NH₄OH 20%) 85/15; ^c CHCl₃/MeOH (2% NH₄OH 20%) 90/10; ^dCHCl₃/MeOH (2% NH₄OH 20%) 95/5

Complexes	TLC, <i>R_f</i>	Yield %
[^{99m} Tc(NPh)(PNHP)(O,N-ap)]	0.42 ^b	62
[^{99m} Tc(NPh)(PNMeP)(O,N-ap)]	0.24 ^a ; 0.45 ^b ; 0.14 ^c	97
[^{99m} Tc(NPh)(PNMeP)(S,N-atp)]	0.28 ^a ; 0.28 ^c	85
[^{99m} Tc(NPh)(PNMeP)(O,O-cat)]	0.85 ^a ; 0.85 ^c ; 0.5 ^d	91
[^{99m} Tc(NPh)(PNMeP)(S,O-tsal)]	0.78 ^a ; 0.75 ^c ; 0.35 ^d	90
[^{99m} Tc(NPh)(PNMeP)(S,S-bdt)]	0.74 ^a ; 1 ^{b,c,d}	98


R_f values shown by the compounds of Table 1 are in full accord with the ones shown by the corresponding compounds obtained at macroscopic level, using ⁹⁹Tc, thus confirming that for the compounds of the invention the transfer from macro to micro level is possible.

The metal-imido hetero-diphosphine complexes of the present invention proved useful in the radiopharmaceutical field, either in radiodiagnostic imaging, when ^{99m}Tc is the employed radioactive metal, or in radiotherapy, when ¹⁸⁶Re and ¹⁸⁸Re are the radioactive metals.

Accordingly, the invention encompasses also the use of these complexes in the diagnostic and/or therapeutic radiopharmaceutical field and the pharmaceutical compositions comprising said compounds in admixture with pharmaceutically acceptable carriers and/or excipients.

CLAIMS

1. A radioactive transition metal-imido hetero-diphosphine complex compound of formula (I):




wherein:

Me is a radioactive transition metal selected from the group consisting of $^{99\text{m}}\text{Tc}$, ^{186}Re , ^{188}Re ;

10 R is a $\text{C}_1\text{-C}_{15}$ linear or branched alkyl or alkenyl residue, optionally interrupted by -O-, -S-, -N(R')-, where $\text{R}' = \text{H}$ or $\text{C}_1\text{-C}_6$ alkyl, and/or optionally substituted with halogen, hydroxy, $\text{C}_1\text{-C}_5$ alkoxy, carboxy, ester, thiol, primary or secondary amino or amido, groups, or R is phenyl or an aryl residue, being R optionally substituted with a biologically active substance, wherein said biologically active substance is selected among sugars, amino
15 acids, fatty acids, vitamins, hormones, peptides, catecholamines, said catecholamines being optionally conjugated, via peptidic bond, to the other above mentioned biologically active substances;

L^1 is a tridentate hetero-diphosphine ligand of formula (II):



(II).

20 wherein:

R^1 , R^2 , R^3 and R^4 , which may be the same or different, have the same meanings as R;

X is oxygen, sulphur, NR^5 , wherein R^5 is hydrogen or R;

n is an integer ranging from 1 to 5;

25 L^2 is a bidentate ligand, which comprises a combination of two donor atoms, selected from the group consisting of oxygen, sulphur and nitrogen,

said atoms being preferably negatively charged and being separated by a spacer of 2 to 4 members, said spacer being an aliphatic chain or part of an aromatic ring, L^2 being optionally conjugated to a biologically active substance as above defined;

5 Z^- is a mononegative counter-ion selected from the group consisting of Cl^- , Br^- , OH^- , ClO_4^- , EtO^- , tetrafluoroborate .





2. A radioactive transition metal-imido hetero-diphosphine complex according to claim 1, wherein the radioactive transition metal is ^{99m}Tc .

3. A radioactive transition metal-imido hetero-diphosphine complex
10 according to any of the preceding claims, wherein R is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, octyl, decyl, dodecyl, propenyl, butenyl, pentenyl, phenyl, benzyl, tolyl, 4-methoxy-benzyl, 4-ethoxy-benzyl, salicyl.

4. A radioactive transition metal-imido hetero-diphosphine complex
15 according to claim 3, wherein R is substituted with a biologically active substance, said substance being a catecholamine selected from the group consisting of dopamine, L-DOPA, 3-hydroxythyramine, optionally conjugated, via peptide bond, to another biologically active substance of claim 1.

5. A complex according to claim 4, wherein dopamine is conjugated to
20 vitamin H.

6. A radioactive transition metal-imido hetero-diphosphine complex according to claim 1, wherein L^1 is selected from the group consisting of:



7. A radioactive transition metal-imido hetero-diphosphine complex according to claim 1, wherein L^2 comprises a combination of two electron-donor atoms selected from the group consisting of $[O^-, O^-]$, $[N^-, O^-]$, $[S^-, O^-]$, $[N^-, N^-]$, $[N^-, S^-]$ and $[S^-, S^-]$, said atoms being separated by a 2 to 4 membered
5 spacer, wherein said spacer is an aliphatic chain or part of an aromatic ring .

8. A complex according to claim 7, wherein L_2 is selected from the group consisting of catecholate⁽²⁻⁾; carbonate⁽²⁻⁾; 1,2-phenylenediaminate⁽²⁻⁾; 1,2-benzenedithiolate⁽²⁻⁾; ethyleneglycolate⁽²⁻⁾; ethylenediaminate⁽²⁻⁾; ethylenedithiolate⁽²⁻⁾; 1,2-aminophenolate⁽²⁻⁾; 1,2-aminothiophenolate⁽²⁻⁾;
10 thiosalicilate⁽²⁻⁾; 1,2-aminoethanolate⁽²⁻⁾.


9. A complex according to claim 7, wherein L_2 is conjugated to a catecholamine selected from the group consisting of dopamine, L-DOPA, 3-hydroxytyramine, optionally conjugated to another biologically active substance of claim 1.

15 10. A complex according to claim 9, wherein dopamine is conjugated to vitamin H.

11. A radioactive transition metal-imido hetero-diphosphine complex according to claim 1, wherein Z^- is Cl^- , ClO_4^- , EtO^- , tetrafluoroborate.

12. A process for the preparation of the radioactive compounds of formula
20 (I) comprising the following steps:

- reacting an oxide of a transition metal MeO_4^- with an excess of tertiary monophosphine, in a hydro-alcoholic solution acidified with hydrochloric acid and in the presence of 1-substituted-2-acetyl hydrazine, to give an imido complex of formula (IV):




wherein:

Me is $^{99m}TcO_4^-$, $^{186}ReO_4^-$, $^{188}ReO_4^-$;

R is as defined in Claim 1;

Y is Cl, Br, OH,

- reacting said compound of formula (IV) with a tridentate hetero-diphosphine ligand L^1 , in organic solvents selected from alcohols, chlorinated solvents, acetonitrile or a mixture thereof, optionally in the presence of an organic base, at a temperature ranging from room temperature to the reflux temperature of the solvent, to give the intermediate compound of formula (III):



wherein:


- Me, R, Y, L^1 are as defined above,

- reacting said intermediate compound of formula (III) with a bidentate ligand L^2 in alcoholic solution, after adjusting pH at 7.4 with phosphate buffer.

13. A process according to claim 12, wherein said 1-substituted-2-acetyl hydrazine is 1-phenyl-2-acetyl hydrazine.

14. A process according to claim 12, wherein the oxide of the transition metal is ^{99m}TcO .

15. An intermediate compound of formula (III):



- wherein Me, R, Y, L^1 are as above defined.

16. A radioactive transition metal-imido hetero-diphosphine complex of formula (I) for use in radiodiagnostic imaging.

17. A radioactive transition metal-imido hetero-diphosphine complex of formula (I) for use in radiotherapy.

18. A pharmaceutical composition comprising a radioactive transition metal-imido hetero-diphosphine complex of formula (I) in admixture with pharmaceutically acceptable carriers and/or excipients.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/12128

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K51/04 C07F9/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 91/03262 A (AMERSHAM INTERNATIONAL PLC, UK) 21 March 1991 (1991-03-21) cited in the application page 21, line 22 - line 25	1-3,6-9, 11,15
A	claims 8-10	4,10, 12-14, 16-18
A	EP 0 949 265 A (NIHON MEDIPHYSICS CO LTD) 13 October 1999 (1999-10-13) figure 10	1-18
	----- -/-- -----	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

29 March 2004

Date of mailing of the international search report

15/04/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Richter, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/12128

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ARTERBURN J B ET AL: "Functionalized organoimidorhenium(V) complexes as potential radiopharmaceuticals: syntheses of glycine derivatives and the structure determination of a rhenium analog of chlorambucil"</p> <p>CAPLUS, 1997, XP002227307 abstract</p> <p>& ARTERBURN J B ET AL: "FUNCTIONALIZED ORGANOIMIDORHENIUM (V) COMPLEXES AS POTENTIAL RADIOPHARMACEUTICALS: SYNTHESIS OF GLYCINE DERIVATIVES AND THE STRUCTURE DETERMINATION OF A RHENIUM ANALOGUE OF CHLORAMBUCIL" ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 35, no. 23/24, 3 January 1997 (1997-01-03), pages 2877-2879, XP000641473 ISSN: 0570-0833</p> <p>-----</p>	1,3,15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/12128

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9103262	A	21-03-1991	AT 131072 T	15-12-1995
			CA 2039732 A1	01-03-1991
			DE 69024038 D1	18-01-1996
			EP 0441953 A1	21-08-1991
			WO 9103262 A1	21-03-1991
			JP 4506810 T	26-11-1992
			JP 3221875 B2	22-10-2001
			JP 3341001 B2	05-11-2002
			JP 2002060397 A	26-02-2002
			US 5589576 A	31-12-1996
			US 6124440 A	26-09-2000
			US 6329513 B1	11-12-2001
			US 6001979 A	14-12-1999
			US 2002082398 A1	27-06-2002
<hr/>				
EP 0949265	A	13-10-1999	AT 239745 T	15-05-2003
			AU 730120 B2	22-02-2001
			AU 5412898 A	15-07-1998
			CA 2275451 A1	25-06-1998
			DE 69721820 D1	12-06-2003
			DE 69721820 T2	26-02-2004
			DK 949265 T3	11-08-2003
			EP 0949265 A1	13-10-1999
			US 6270745 B1	07-08-2001
			ES 2193407 T3	01-11-2003
			WO 9827100 A1	25-06-1998
			KR 2000057661 A	25-09-2000
			NZ 335950 A	23-06-2000
			US 2002048549 A1	25-04-2002
<hr/>				